Next Step After 'Right To Try'? Senate Hearing Includes Call To Reopen Orphan Drug Act
Executive Summary
Trump Administration’s successful campaign to pass “Right to Try” legislation may be emboldening advocates to push for other policies that will loosen FDA regulatory requirements on rare disease drug development.
You may also be interested in...
XLH Patient Meeting Showcases Value Of Post-Approval Feedback To US FDA
X-Linked Hypophosphatemia patient feedback meeting follows recent approval of Ultragenyx’ Crysvita. Like an SMA meeting in 2017, it showed how post-approval meetings can help sustain momentum in a new class.
Gottlieb's "Right To Try" Sentiment: Law Fails To Address Difficulties Faced By Drugmakers
US FDA Commissioner suggests Congress may need to explore incentives for drugmakers to make investigational products available in the pre-approval phase.
Orphan Drug Act: Congressional, FDA, NORD Reviews Come Amid Pricing Debate
Republican Senators request US Government Accountability Office quantify law’s impact and assess whether regulatory or legislative changes are needed. FDA plans ‘unbiased’ look at outcomes from law’s incentives, while NORD is developing data on total percentage of drug spending represented by orphan indications.